INTRODUCTION
Multiple levels of immune dysfunction have been found in patients with cirrhosis rendering them susceptible to various bacterial infections [1] .
Infectious episodes are common causes of clinical deterioration in this patient group [2] as they play a substantial role in the development of disease specific complications and mortality [3, 4] . Prevention of bacterial infections in cirrhosis is of paramount importance, which requires early identification of patients at high risk for the development of these episodes. Only some clinical predictors of bacterial infections, such as advanced disease stage [5] and the presence of gastrointestinal hemorrhage [6] have been known for a long while. Recently, various genetic polymorphisms affecting different functions of innate immune system were identified to have a substantial impact on the development of bacterial infections in cirrhosis. These functional variations, assessed either by serologic [7, 8] or single nucleotide polymorphism(SNP) based genetic methods [9] [10] [11] [12] , are considered to further abolish the pre-existing immune dysfunction in cirrhosis. Most of these studies, however focused on one or two single markers and primarily assessed the risk for the development of spontaneous bacterial peritonitis(SBP) and not for other type of bacterial infections. Nonetheless, in cirrhosis, SBP comprises only up to 25% of the infectious episodes.
Lectin pathway molecules of the complement system are synthesized in the liver and have pivotal roles in the innate host defense against infectious organisms. Mannose-binding lectin(MBL) and ficolins(FCNs) act as soluble pattern recognition molecules(sPRM), while mannan-binding lectin serine proteases(MASPs) do as effector molecules in elimination of the pathogens F o r P e e r R e v i e w 6 [13] . Low levels of the functional proteins increase the risk of various infectious diseases mostly in immune-deficient conditions [14] [15] [16] .
Association of deficiencies in lectin pathway molecules with the development of infectious episodes in patients with cirrhosis is quite reasonable, but has scarcely been investigated. Our group has previously demonstrated, that the absolute MBL deficiency is a risk for the development of clinically significant bacterial infections (CSI) independently from both the disease severity and the presence of co-morbidity. Furthermore, in a small study of Chong et al.,
the MBL2 deficient genotype predisposed patients with hepatitis B virus(HBV)
induced liver cirrhosis to develop SBP [17] .
In the present study, we aimed to assess the serum levels of various lectin pathway molecules in a large cohort of stable outpatients with cirrhosis and also their association with the disease specific characteristics.
Additionally, in a 5-year follow-up observational study we aimed to evaluate whether serum levels of various lectin pathway molecules constitute a risk for the development of cirrhosis-associated bacterial infections.
PATIENTS AND METHODS

Patient population
We performed a cohort study among adult patients with established diagnosis of cirrhosis of different etiologies in a tertiary care referral center of Hungary 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w   7 the outpatient clinic during regular or extraordinary follow-up visits and also from the inpatient ward owing to hospitalization with an acute decompensation (AD) episode [18] . In this study only stable outpatients with available serum samples (n=266) were included.
Clinical characteristics of patients at inclusion are presented in Table 1 .
Blood samples, routine laboratory data and detailed clinical phenotype were captured at inclusion. Clinical data were determined by in-depth review of the patients' medical records using a structured interview. Medical records that documented age at diagnosis, etiology, presence of hepatocellular carcinoma, esophageal varices, extrahepatic co-morbidities, history of previous AD episode(s), and cirrhosis-related medication were retrospectively analyzed for the period prior to the observational follow-up study. At enrolment, disease severity assessed by liver-oriented scores (Child-Pugh and MELD) was determined.
Phenotypical characterization of patients during follow-up
Patients were enrolled into an observational follow-up study, where the attending gastroenterologist registered date and type of clinically significant bacterial infections (CSI) warranted hospital admission. Follow-up period lasted 5 years, or until death/loss of follow-up. The median follow-up was 979 days (IQR: 331-1825). Collected data were transferred and stored in a database. At the end of the study period, December 31, 2013, all clinical data were extracted for further analysis.
Development of CSI was carefully established by compatible clinical symptoms and findings, laboratory data (leucocyte count, high-sensitivity C- The healthy control group consisted of 160 age-and gender-matched individuals (male/female: 72/88, age: 51.5±16.9 years) selected from consecutive blood donors in Debrecen. The control subjects did not have any 
Serological analysis
Blood samples were obtained at enrolment from each patient and were frozen at -70°C until testing collectively after end of the study period.
Serum level of MASP-2 was determined by a commercially available solid-phase enzyme-linked immunoassay(ELISA), according to the manufacturer's instructions (Hycult Biotechnology, Uden, Netherlands).
MASP-2 deficiency was defined a level of <100ng/ml in agreement with literature data [24] . [San Diego, CA] programs were used. A 2-sided probability value of <0.05 was considered to be statistically significant. Table 2 . FCN-2, FCN-3 and MASP-2 levels were significantly lower in patients with cirrhosis compared to healthy subjects.
RESULTS
Serum levels of lectin pathway molecules in cirrhosis
Similarly, MASP-2 deficiency occurred more often in patients with cirrhosis.
In cirrhosis, levels of all three lectin pathway molecules decreased gradually according to disease severity, as rated by the Child-Pugh stage.
Furthermore, both types of the FCNs but not the MASP-2 levels were significantly lower in patients with ascites as compared to those without (Table 2) .
FCN levels were also associated with disease etiology to some degree. Table 2 ).
Significant correlation was found between levels of lectin pathway molecules and laboratory markers of impaired renal and liver function and accordingly with liver-oriented scores (Child-Pugh and MELD). Nonparametric correlations are summarized in Table 3 .
Significance of serum levels of lectin pathway molecules in the risk of clinically significant bacterial infections
Ninety-five (35.7%) of involved patients encountered at least one episode of CSI during the follow-up period. The median time to the development of first Figure 1A ). No similar association was found, however, in the case of MASP-2 deficiency either individually ( Table 4 and Figure 1B ) or in combination with FCN levels (data not shown).
Covariates
Analysis of clinical factors associated with development of CSI, using univariate Cox regression analysis, is shown in 
Multivariate analysis
Cox regression analysis and the backward elimination procedure, taking (Figure 1E and F) . 
DISCUSSION
To our knowledge, this is, to date the largest study to investigate the complex association between serum levels of the lectin pathway molecules and the disease etiology along with severity in a large cohort of patients with cirrhosis.
Of the lectin pathway molecules of the complement system, two sPRMs (FCN-2 and FCN-3) and one effector molecule were evaluated (MASP-2).
Serum concentrations of the lectin pathway components were found to show large inter-individual variations in healthy adults [25] . In the present study MASP-2 levels [26] and occurrence of MASP-2 deficiency [24] corresponded to those reported previously, while FCN-2 and FCN-3 levels were lower. In the case of MASP-2, we applied a commercially available assay that is widely used in complement studies [24] . In a large group of stable outpatients with cirrhosis (n=266), we found that serum levels of all three molecules were significantly lower compared to healthy controls. Two previous reports verify our findings. In a study of Laursen et al. [28] , low levels of FCN-2 and FCN-3 were found in a small group of patients (n=20) with stable alcoholic cirrhosis compared with healthy controls. Likewise, significantly lower FCN-2 levels were reported in patients [29] .
Contrary, in a single study of patients with chronic HCV infection [30] , serum FCN-2 levels were significantly higher in patients with cirrhosis (n=21) than those in the control and other patient groups including chronic inactive or active HCV patients without cirrhosis. The reason, why serum levels of lectin pathway molecules are decreased in most of the patients with cirrhosis is yet to be elucidated. One reasonable explanation could be that in cirrhosis, synthetic capacity of hepatocytes is damaged, that results in a decreased production of these proteins. This assumption is supported by our findings that FCN-2, FCN-3 and MASP-2 levels showed gradual decrease according to disease severity.
When the adaptive immune response is immature or compromised, the innate immune system constitutes the principle defense against infection.
Clinical studies have shown that common functional gen polymorphisms in FNC2 [27] , FCN3 [16] and MASP2 [15] , which affect the composition, structure and function of respective proteins, confer an increased risk for various bacterial infections particularly in immunocompromised patients.
Cirrhosis has been characterized as an acquired immunodeficiency syndrome [31] . Thus, it is reasonable to assume that serum levels of the lectin pathway molecules might be related to the bacterial infectious episodes among patients with cirrhosis; however, it has not been evaluated so far. Accordingly, we conducted a follow-up observational study to assess whether the low level of FCNs or MASP-2 deficiency constitutes a risk for the development of CSI in patients with cirrhosis.
Several SNPs in the promoter and the encoding region of FCN2 and After lectin type sPRMs bind their targets, MASPs are cleaved and activated and set in motion a proteolytic cascade, which culminates in formation of the membrane attack complex and pathogen lysis [15] . In the present study, serum MASP-2 level was not associated with the risk of developing a CSI. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Finally, serum level of lectin pathway components at enrolment was also not associated with the infection-related mortality. Since complement system has a dual role in disease susceptibility, one can expect that during an on-going inflammatory process rather its excessive activation with subsequent tissue damage than its lack of activity poses a risk of harm to the host.
Another important consideration is that serum level of these molecules might change during acute phase reactions like bacterial infection. We did not reassess serum samples during the first CSI episodes, which is evidently another limitation of this analysis. These issues warrant further evaluation in future studies of the lectin pathway in cirrhosis.
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